Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.
John L Higgins, Insider at Ligand Pharmaceuticals (NASDAQ:LGND), made a large insider sell on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Higgins sold 3,000 shares of Ligand Pharmaceuticals at a price of $160.50. The total transaction amounted to $481,500. Following the transaction, Higgins still owns 335,095 shares of the company, worth $53,065,644. Ligand Pharmaceuticals shares are trading dow
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.